Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma

• DOI: 10.1136/jitc-2020-001679
• Publication Date: 2020-12-23T21:47:54Z
• Authors: Motoki Nakamura; Kotaro Nagase; Maki Yoshimitsu; Tetsuya Magara; Yuka Nojiri; Hiroshi Kato; Tadahiro Kobayashi; Yukiko Teramoto; Masahito Yasuda; Hidefumi Wada; Toshiyuki Ozawa; Yukie Umemori; Dai Ogata; Akimichi Morita
• Keywords: Adult; Aged, 80 and over; Male; 0301 basic medicine; Skin Neoplasms; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Gene Expression; Glucosephosphate Dehydrogenase; Middle Aged; B7-H1 Antigen; Up-Regulation; 3. Good health; Carcinoma, Merkel Cell; 03 medical and health sciences; Immunotherapy Biomarkers; Humans; Female; RNA, Neoplasm; RC254-282; Aged

Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer. Some cases have good prognosis spontaneous regression can occur. Reported prognostic markers, such as polyoma virus infection or programmed death ligand-1 (PD-L1) expression, remain insufficient for precisely estimating the vastly different patient outcomes. We performed RNA sequencing to evaluate immune response comprehensively estimate values of immunogenic factors in patients with MCC.We collected 90 specimens from 71 53 blood serum samples 21 MCC at 10 facilities. The mRNA was extracted formalin-fixed paraffin-embedded tissues. Next-generation sequencing, immunohistochemical staining tests were performed.Next-generation results classified into two types: 'immune active type' associated better clinical outcomes than 'cell division type'. Expression glucose-6-phosphate dehydrogenase (G6PD) gene significantly upregulated Among 395 genes, G6PD expression correlated presence lymph node distant metastases during disease course negatively PD-L1 expression. Immunohistochemical also disease-specific survival exhibited less heterogeneity compared activity could be measured by test. detection increased cancer stage progressed decreased after treatment.G6PD an immunohistochemically serum-detectable marker that levels, used predict immunotherapy response.